These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35619963)

  • 21. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
    Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
    Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
    Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
    J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study.
    Tsai YT; Fang KH; Hsu CM; Lai CH; Chang SW; Huang EI; Tsai MS; Chang GH; Luan CW
    Front Oncol; 2022; 12():825967. PubMed ID: 35242712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis.
    Yang C; Ren G; Yang Q
    Front Surg; 2022; 9():1094973. PubMed ID: 36700011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients.
    Cho A; Untersteiner H; Hirschmann D; Fitschek F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM
    J Neurooncol; 2021 Jan; 151(2):257-265. PubMed ID: 33179214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
    Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
    J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.
    Ni XF; Wu J; Ji M; Shao YJ; Xu B; Jiang JT; Wu CP
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):402-409. PubMed ID: 30178541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.
    Hirahara N; Matsubara T; Kaji S; Kawabata Y; Hyakudomi R; Yamamoto T; Uchida Y; Ishitobi K; Takai K; Tajima Y
    Oncotarget; 2020 Nov; 11(45):4169-4177. PubMed ID: 33227100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients.
    Lv Y; Pan Y; Dong C; Liu P; Zhang C; Xing D
    Med Sci Monit; 2017 Aug; 23():3780-3788. PubMed ID: 28775246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of hand grip strength and modified Glasgow prognostic score predicts clinical outcomes in patients with liver cancer.
    Chen Y; Ruan GT; Shi JY; Liu T; Liu CA; Xie HL; Song MM; Wang ZW; Hu CL; Zhang HY; Zhang XW; Tian HY; Ge YZ; Yang M; Liu YY; Lin SQ; Liu XY; Zheng X; Wang KH; Cong MH; Shen X; Wang X; Deng L; Shi HP
    Front Nutr; 2023; 10():1062117. PubMed ID: 36923698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
    Matsubara T; Takamori S; Haratake N; Toyozawa R; Miura N; Shimokawa M; Yamaguchi M; Seto T; Takenoyama M
    J Thorac Dis; 2020 Apr; 12(4):1520-1528. PubMed ID: 32395289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
    Hanai N; Sawabe M; Kimura T; Suzuki H; Ozawa T; Hirakawa H; Fukuda Y; Hasegawa Y
    Oncotarget; 2018 Dec; 9(97):37008-37016. PubMed ID: 30651931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Finkle JH; Penney BC; Pu Y
    Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection.
    Cao X; Zheng YZ; Liao HY; Guo X; Li Y; Wang Z; Zhang L; Wang XD; Wang X
    Ther Adv Med Oncol; 2020; 12():1758835920970063. PubMed ID: 33224277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
    Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
    Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.